Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):121-31. Review.

PMID:
17261491
2.

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

J Pediatr Psychol. 2007 Jul;32(6):711-27. Epub 2007 Jun 7. Review.

3.

Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.

Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ.

J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. Epub 2012 Sep 5. Review.

PMID:
23021476
4.

Economic implications of attention-deficit hyperactivity disorder for healthcare systems.

Leibson CL, Long KH.

Pharmacoeconomics. 2003;21(17):1239-62. Review.

PMID:
14986737
5.

[The health economics of attention deficit hyperactivity disorder in Germany. Part 1: Health care utilization and cost of illness].

Schlander M, Trott GE, Schwarz O.

Nervenarzt. 2010 Mar;81(3):289-300. Review. German.

PMID:
20232510
6.

[Overall burden to society caused by hyperkinetic syndrome (HKS) and attention deficit hyperactivity disorder (ADHD)].

Schöffski O, Sohn S, Happich M.

Gesundheitswesen. 2008 Jul;70(7):398-403. doi: 10.1055/s-0028-1082049. Review. German.

PMID:
18729028
7.

Impact of comorbidity in adults with attention-deficit/hyperactivity disorder.

Biederman J.

J Clin Psychiatry. 2004;65 Suppl 3:3-7. Review.

8.

Epidemiology of attention-deficit/hyperactivity disorder across the lifespan.

Polanczyk G, Rohde LA.

Curr Opin Psychiatry. 2007 Jul;20(4):386-92. Review.

PMID:
17551354
9.

The search for biomarkers for attention deficit/hyperactivity disorder.

Wallis D.

Drug News Perspect. 2010 Sep;23(7):438-49. doi: 10.1358/dnp.2010.23.7.1472296. Review.

PMID:
20862396
10.

[Detailed review of epidemiologic studies on adult Attention Deficit/Hyperactivity Disorder (ADHD)].

Simon V, Czobor P, Bálint S, Mészáros A, Murai Z, Bitter I.

Psychiatr Hung. 2007;22(1):4-19. Review. Hungarian.

PMID:
17558040
11.

Epidemiology of ADHD in school-age children.

Scahill L, Schwab-Stone M.

Child Adolesc Psychiatr Clin N Am. 2000 Jul;9(3):541-55, vii. Review.

PMID:
10944656
12.

Variations in prevalence of attention deficit hyperactivity disorder worldwide.

Skounti M, Philalithis A, Galanakis E.

Eur J Pediatr. 2007 Feb;166(2):117-23. Epub 2006 Oct 11. Review.

PMID:
17033803
13.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
14.
15.

Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum.

Greydanus DE, Pratt HD, Sloane MA, Rappley MD.

Pediatr Clin North Am. 2003 Oct;50(5):1049-92, vi. Review.

PMID:
14558681
16.

Epidemiologic considerations in attention deficit hyperactivity disorder: a review and update.

Polanczyk G, Jensen P.

Child Adolesc Psychiatr Clin N Am. 2008 Apr;17(2):245-60, vii. doi: 10.1016/j.chc.2007.11.006. Review.

PMID:
18295145
17.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
18.

The consequences of attention-deficit/hyperactivity disorder in adults.

Goodman DW.

J Psychiatr Pract. 2007 Sep;13(5):318-27. Review.

PMID:
17890980
19.

Economic costs of diabetes in the U.S. In 2007.

American Diabetes Association.

Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Review. Erratum in: Diabetes Care. 2008 Jun;31(6):1271.

PMID:
18308683
20.
Items per page

Supplemental Content

Write to the Help Desk